retatrutide vendors and the Grey Market: Buyer Beware – Sarah Hormachea Retatrutide: What Clinicians Should Know

The FDA has approved specific GLP-1 formulations for weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity

They come with a US Boxed Warning of a risk of thyroid C-cell tumors and medullary thyroid carcinoma and are contraindicated in patients with multiple endocrine neoplasia syndrome type 2

Assisted by Per Olaf Huusfeldt and Per Franklin Nielsen, two chemists from another division in the company, Knudsen succeeded in her mission by adding a spacer between the fatty acid and synthetic GLP-1

Both Ozempic and Rybelsus can also be prescribed off-label to treat obesity